À¯·´ ¹× Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå ±Ô¸ð ¹× ¿¹Ãø, ¼¼°è ¹× Áö¿ª Á¡À¯À², µ¿Çâ, ¼ºÀå ±âȸ ºÐ¼®, ¸®Æ÷Æ® ¹üÀ§ : Á¦Ç° À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®
Europe and Middle East Spinal Cord Stimulation Devices for Chronic Pain Market Size and Forecasts, Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type, Application, End User, and Regional Analysis
»óǰÄÚµå : 1408665
¸®¼­Ä¡»ç : The Insight Partners
¹ßÇàÀÏ : 2023³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 204 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,450 £Ü 4,819,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù.
US $ 4,450 £Ü 6,216,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,450 £Ü 7,613,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

À¯·´¡¤Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀåÀº 2022³â 8¾ï 9,200¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 15¾ï 7,300¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖÀ¸¸ç, 2022-2030³âÀÇ CAGRÀº 7.3%·Î ¿¹ÃøµË´Ï´Ù. ô¼ö ¼Õ»óÀÇ Áõ°¡ ¹× À¯·´¿¬ÇÕ(EU)¿¡¼­ Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ ÀÌ¿ë °¡´É¼ºÀº À¯·´¡¤Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¸î°³ÀÇ ¿äÀÎÀÔ´Ï´Ù.

ô¼öÀڱرâ´Â ³·Àº ¼öÁØÀÇ Àü±â¸¦ ô¼ö¿¡ Á÷Á¢ Èê·Áº¸³» ÅëÁõÀ» ¿ÏÈ­ÇÏ´Â À̽ÄÇü ÀåºñÀÔ´Ï´Ù. ôÃß Àڱرâ´Â ´ëºÎºÐ ºñ¼ö¼úÀû ÅëÁõ Ä¡·á ¿É¼ÇÀ¸·Î ÃæºÐÇÑ ¿ÏÈ­¸¦ ¾òÁö ¸øÇßÀ» ¶§ »ç¿ëµË´Ï´Ù. ¶ÇÇÑ Ã´¼ö Àڱرâ´Â Àü¹ÝÀûÀÎ »ýȰ°ú ¼ö¸éÀÇ ÁúÀ» °³¼±Çϰí ÁøÅëÁ¦ÀÇ Çʿ伺À» °¨¼Ò½Ãų ¼ö ÀÖ½À´Ï´Ù. ÀϹÝÀûÀ¸·Î ´Ù¸¥ ÅëÁõ °ü¸® Ä¡·á¿Í ÇÔ²² »ç¿ëµË´Ï´Ù.

À¯·´ ¿¬ÇÕÀÇ Çõ½ÅÀû Ä¡·á¹ý ÀÌ¿ë °¡´É¼º

À¯·´À§¿øÈ¸°¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é ô¼ö ¼Õ»óÀº °¨°¢ »ó½ÇÀ» µ¿¹ÝÇÑ ¿îµ¿ Àå¾Ö, ¸¸¼º ÅëÁõ ¹× ±âŸ ¿îµ¿ ±â´É Àå¾Ö¸¦ À¯¹ßÇÏ´Â ¿øÀÎÀÌ µË´Ï´Ù. ÀÌ¿¡ µû¶ó À¯·´¿¬ÇÕ(EU)Àº ô¼ö ¼Õ»ó ȯÀÚ¸¦ À§ÇÑ ¿©·¯ ÀçȰ ÇÁ·Î±×·¥À» ½ÃÇàÇϰí ÀÖ½À´Ï´Ù. EUÀÇ °úÇÐÀÚµéÀÌ ´ÙÇÐÁ¦ÀûÀ¸·Î Çù·ÂÇϰí Àִ ô¼ö º¹±¸ ÇÁ·ÎÁ§Æ®(SCRP)µµ ±× Áß Çϳª·Î, ô¼ö ¼Õ»ó ÈÄ ¿îµ¿ ±â´É ¹× µ¿ÀÛ°ú °°Àº ½ÅüÀû ¿òÁ÷ÀÓÀ» ȸº¹ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ ÇÁ·Î±×·¥ÀÇ ÀÏȯÀ¸·Î ÀÓ»ó½ÃÇèÀÇ ÀÏȯÀ¸·Î ÁãÀÇ ¿îµ¿ µ¿ÀÛÀ» Ç¥ÁØÈ­Çϱâ À§ÇÑ ½ÇÇè ÀåºñÀÎ ¸ðÅä·¹ÀÌÅÍ(MotoRater)°¡ °³¹ßµÇ¾î »óÇ¥ µî·ÏÀ» ¸¶ÃƽÀ´Ï´Ù. ÀÌµé ¼³Ä¡·ù´Â ¿îµ¿ ±â´ÉÀ» ´ã´çÇÏ´Â EphA4¿Í °°Àº ÈïºÐ¼º ÁßÃß ÆÐÅÏ ¹ß»ý±â(CPG) ´º·±ÀÇ ¼¼Æ÷ Ư¼ºÀ» È®ÀÎÇÏ°í Æ¯¼ºÈ­Çϱâ À§ÇØ È°¿ëµÇ¾úÀ¸¸ç, CPG´Â ô¼ö¿¡ ÀÖ´Â ½Å°æÈ¸·Î·Î CPG ´º·±°ú ½Ã³À½º »óÈ£ ÀÛ¿ëÀÇ »óÈ£ ÀÛ¿ëÀ¸·Î ÀÎÇØ ¸®µë ¿îµ¿À» ÀÚ±ØÇÕ´Ï´Ù. ÀÓ»ó ¿¬±¸ °á°ú´Â ÇÐȸ ¹× ÇÐȸ¸¦ ÅëÇØ ¹ßÇ¥µÇ°í, ƯÇ㸦 Ãâ¿øÇϰí, ÃâÆÇµÇ¾ú½À´Ï´Ù. µû¶ó¼­ EUÀÇ Ã´¼ö ¼Õ»ó Ä¡·á¹ý¿¡¼­ ÇöÀç ÁøÇàÁßÀÎ ±â¼ú Çõ½ÅÀº ô¼ö ¼Õ»óÀ¸·Î °íÅë¹Þ´Â ¼ö¹é¸¸ ¸íÀÇ »ç¶÷µéÀÇ ¿îµ¿ ´É·Â°ú »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ µµ¿òÀ̵ǰí ÀÖ½À´Ï´Ù.

¿©·¯ ¹ÙÀÌ¿À Á¦¾àȸ»çµéÀÌ Ã´¼ö¼Õ»ó Ä¡·á¸¦ À§ÇÑ Çõ½ÅÀûÀÎ Á¦Ç°À» °³¹ßÇϰí ÀÖ½À´Ï´Ù. ½º¿þµ§ÀÇ ¹ÙÀÌ¿ÀÁ¦¾à ±â¾÷ ¹ÙÀÌ¿À¾ÆÅ©Æ½(BioArctic)Àº ÁßÃ߽Űæ°è(CNS) Áúȯ Ä¡·á¹ý °³¹ß¿¡ Àü³äÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2019³â 2¿ù ¹ÙÀÌ¿À¾ÆÅ©Æ½Àº ¼Õ»óµÈ ô¼ö¿¡ ¿Ü°úÀûÀ¸·Î À̽ÄÇÒ ¼ö ÀÖ´Â »ýºÐÇØ¼º ÀÇ·á±â±â SC0806À» °³¹ßÇß½À´Ï´Ù. °æÀï»çµéÀÇ ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Á¦Ç° Ãâ½Ã´Â À¯·´°ú Áßµ¿ÀÇ ¸¸¼ºÅëÁõ ½ÃÀåÀ» À§ÇÑ Ã´¼öÀڱر⠽ÃÀåÀÇ ¼ºÀå¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå µ¿Çâ

Àç»ýÇϰí Çõ½ÅÀûÀÎ ÀÓÇöõÆ®¸¦ ÀÌ¿ëÇÑ Ä¡·á Á¢±Ù ¹æ½Ä

¸¶µå¸®µå ÀÚÄ¡ÁÖ´Â EU¿¡¼­ ÃÖÃÊ·Î ¼¼Æ÷Ä¡·á¿Í Àç»ýÄ¡·á¸¦ ÀÌ¿ëÇÑ Ã´¼ö¼Õ»ó Ä¡·á¸¦ ½Ç½ÃÇß´Ù°í ÁÖÀåÇϰí ÀÖ½À´Ï´Ù. Àç»ýÀÇ·á´Â ôÃß¼Õ»ó ȯÀÚ¿¡¼­ °£¿±Áٱ⼼Æ÷¸¦ ÃßÃâÇϰí, ÃßÃâµÈ ¼¼Æ÷¸¦ ¼¼Æ÷ Á¦Á¶½Ç¿¡¼­ ó¸®ÇÑ ÈÄ, Àç»ýµÈ ¼¼Æ÷¸¦ ôÃß¼Õ»ó ºÎÀ§ ¶Ç´Â ³úô¼ö¾×(CSF)¿¡ ÁÖÀÔÇÏ´Â °ÍÀ» Æ÷ÇÔÇÕ´Ï´Ù. µû¶ó¼­ ÀÌ ±â¼úÀº SCIÀÇ °³ÀÎ ¸ÂÃãÇü Ä¡·á¹ýÀ̶ó°í ÇÒ ¼ö ÀÖ½À´Ï´Ù.

À¯·´À§¿øÈ¸´Â 2022³â 9¿ù º¸°í¼­¸¦ ÅëÇØ °úÇÐÀÚµéÀÌ ³úÁ¹Áß È¸º¹À» µ½±â À§ÇØ ±×·¡ÇÉ ±â¹Ý ÀÓÇöõÆ®¿Í °¡»óÇö½Ç(VR) °ÔÀÓÀ» »ç¿ëÇÏ¿© ³úÁ¹ÁßÀ» Ä¡·áÇÏ´Â »õ·Î¿î ¹æ¹ýÀ» °³¹ßÇϰí ÀÖ´Ù°í ¹àÇû½À´Ï´Ù. °úÇÐÀÚµéÀº ½Å°æ ¼Õ»óÀ» º¹±¸Çϱâ À§ÇØ ÀÌ·¯ÇÑ »õ·Î¿î Á¢±Ù¹ýÀ» ½ÃµµÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ÀϺΠ¿¬±¸ÀÚµéÀº ±×·¡Çɰú °°Àº Àΰø Àç·á¸¦ ÀÌ¿ëÇØ ô¼ö ±¸Á¶¸¦ Áï¼®¿¡¼­ À籸¼ºÇÏ·Á´Â ½Ãµµ¸¦ Çϰí ÀÖ½À´Ï´Ù. ±×·¡ÇÉÀº ô¼öÀÇ ÇüŸ¦ Á¤±³ÇÏ°Ô ¸ð¹æÇÏ´Â 3D ±¸Á¶¸¦ ¸¸µå´Â µ¥ »ç¿ëµË´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ Çõ½ÅÀûÀÎ Àΰø Àç·á¿Í ÀÓÇöõÆ®¸¦ »ç¿ëÇÏ¿© ô¼ö ¼Õ»óÀ¸·Î °íÅë¹Þ´Â ȯÀÚÀÇ Ä¡·á °¡´É¼ºÀ» ¼º°øÀûÀ¸·Î º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. Àç»ýÇϰí Çõ½ÅÀûÀÎ ÀÓÇöõÆ®¸¦ ÀÌ¿ëÇÑ Ä¡·á Á¢±Ù¹ýÀº À¯·´ ¹× Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼öÀڱر⠽ÃÀåÀÇ »õ·Î¿î Æ®·»µå·Î ¶°¿À¸£°í ÀÖ½À´Ï´Ù.

À¯·´ ¹× Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù. Á¦Ç° À¯Çü¿¡ µû¶ó ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀåÀº ÃæÀü½Ä ¹× ºñÃæÀü½ÄÀ¸·Î ³ª´¹´Ï´Ù. ÃæÀü½Ä ºÎ¹®Àº 2022³â¿¡ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022-2030³â »çÀÌ¿¡ »ó´çÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱرâ´Â ¿ëµµº°·Î °íÀ强 ¿äÅë ÁõÈıº, º¹ÇÕ ±¹¼Ò ÅëÁõ ÁõÈıº, ÅðÇ༺ µð½ºÅ© Áúȯ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. º¹ÇÕºÎÀ§ÅëÁõÁõÈıº ºÎ¹®Àº 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2020-2030³âÀÇ ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÃÖÁ¾»ç¿ëÀÚº°·Î´Â ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱرâ´Â º´¿ø, ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC), ±âŸ·Î ºÐ·ùµÇ¸ç, º´¿ø ºÎ¹®ÀÌ 2022³â ½ÃÀå Á¡À¯À²ÀÌ °¡Àå Å©°í 2022-2030³â CAGRÀÌ °¡Àå ³ôÀ» °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

2023³â 9¿ù, Resonant Link¿Í Cirtec Medical Corp´Â À̽ÄÇü ÀÇ·á±â±âÀÇ ¹Ì·¡¸¦ °³Ã´Çϱâ À§ÇØ Á¦ÈÞ¸¦ ¸Î¾ú½À´Ï´Ù. ÀÌ Á¦ÈÞ´Â Resonant LinkÀÇ Â÷¼¼´ë ¹«¼± Àü·Â°ú Cirtec MedicalÀÇ Àü¹®ÀûÀÎ Á¦Ç° ¼³°è, °³¹ß ¹× Á¦Á¶ ¼­ºñ½º¸¦ °áÇÕÇÏ¿© ÀÇ·á±â±â Á¦Á¶¾÷ü¿¡ ÃÖ°íÀÇ ±â¼ú, ¿ÏÀüÈ÷ ÅëÇÕµÈ ÄÄÆ÷³ÍÆ® ¹× ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå À¯·´¡¤Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå : ¿äÁ¡

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå À¯·´¡¤Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå : ½ÃÀå ±¸µµ

Á¦5Àå À¯·´¡¤Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå

Á¦6Àå À¯·´¡¤Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå : Áö¿ª ºÐ¼®

Á¦7Àå À¯·´¡¤Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå - ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø : Á¦Ç° À¯Çüº°

Á¦8Àå À¯·´¡¤Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå - ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø : ¿ëµµº°

Á¦9Àå À¯·´¡¤Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå - ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø : ÃÖÁ¾»ç¿ëÀÚº°

Á¦10Àå À¯·´ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå - ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø : Áö¿ª ºÐ¼®

Á¦11Àå Áßµ¿ÀÇ ¸¸¼º ÅëÁõ¿ë ô¼ö Àڱر⠽ÃÀå - ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø : Áö¿ª ºÐ¼®

Á¦12Àå ¾÷°è »óȲ

Á¦13Àå ±â¾÷ °³¿ä

Á¦14Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Europe and Middle East spinal cord stimulation devices for chronic pain market is expected to grow from US$ 0.892 billion in 2022 to US$ 1.573 billion by 2030; it is expected to grow at a CAGR of 7.3% from 2022 to 2030. rising number of spinal cord injuries and the availability of innovative treatments in the European Union (EU) are a few factors driving the Europe and Middle East spinal cord stimulation devices for chronic pain market growth.

A spinal cord stimulation device is an implanted device that sends low levels of electricity directly into the spinal cord to relieve pain. A spinal cord stimulator is mostly used after non-surgical pain treatment options that have failed to provide sufficient relief. Additionally, a spinal cord stimulator can improve the overall quality of life and sleep and reduce the need for pain medicines. It is typically used along with other pain management treatments.

Availability of Innovative Treatments in the European Union

According to a report published by the European Commission, SCI is responsible for causing motor impairment with sensation loss, chronic pain, and other locomotor dysfunction. Therefore, in the European Union (EU), several rehabilitation programs are being conducted for patients living with SCIs. The SPINAL CORD REPAIR Project (SCRP) is one such example that is a multidisciplinary collaboration among EU scientists. The SCRP is responsible for restoring physical movements such as motor function or movement after SCIs. Under this program, an experimental setup-MotoRater-was developed and trademarked for the standardized testing of locomotion movements among rodents as a part of clinical testing. These rodents were utilized to identify and characterize the cellular properties of excitatory central pattern generator (CPG) neurons such as EphA4, which are responsible for locomotion. CPG is a neural circuit in the spinal cord that stimulates rhythmic movements from the interplay between CPG neurons and their synaptic interactions. The clinical research results were presented through meetings and congresses; patents were filed and published. Therefore, the ongoing innovations in the treatments of spinal cord disorders in the EU help improve the mobility and quality of life for millions suffering from SCI.

Several biopharma companies are developing innovative products to treat SCIs. BioArctic, a Swedish biopharma company, is dedicated to developing treatments for central nervous system (CNS) disorders. For instance, in February 2019, BioArctic developed "SC0806," a biodegradable medical device that is surgically implanted into an injured spinal cord. Upon the implantation of "SCO806," the device guides nerve fibers across the injured area in the spinal cord. Such innovative product launches by competitive players to treat SCI fuel the growth of spinal cord stimulation devices for the chronic pain market in Europe and the Middle East.

Market Trend

Regenerative and Innovative Implant-Based Therapeutic Approaches

The Comunidad de Madrid claims to be the first in the EU to provide treatments for SCIs using cell and regenerative therapy. Regenerative medicine includes the extraction of mesenchymal stem cells from patients suffering SCIs, treating the extracted cells in a cell production room, and then injecting the regenerated cells at the exact site of SCI or into the cerebrospinal fluid (CSF). Thus, this technique serves as a personalized treatment for SCIs.

The European Commission published a report in September 2022 revealing that scientists are developing new ways to treat SCI using graphene-based implants and virtual reality (VR) gaming to help improve stroke recovery. Scientists are trying these new approaches to reverse nerve damage, while some researchers are attempting to reshape the architecture of the spinal cord in situ by using engineered materials such as graphene. Graphene is used to create a 3D structure that would skillfully mimic the morphology of the spinal cord. Therefore, the use of such innovative engineered materials and implants successfully exhibits the treatment potential in patients suffering from SCIs. The regenerative and innovative implant-based therapeutic approaches are emerging as new trends in Europe and the Middle East spinal cord stimulation devices for the chronic pain market.

The "Europe and Middle East Spinal Cord Stimulation Devices for Chronic Pain Market" is segmented on the basis of product type, application, end-user, and region. Based on product type, the spinal cord stimulation devices for chronic pain market is bifurcated into rechargeable and non-rechargeable. The rechargeable segment held the largest market share in 2022, and the same segment is expected to record a significant CAGR during 2022-2030. Based on application, the spinal cord stimulation devices for the chronic pain market are segmented as failed back syndrome, complex regional pain syndrome, degenerative disk disease, and others. The complex regional pain syndrome segment held the largest market share in 2022, and the same segment is anticipated to register the highest CAGR for the forecast period 2020-2030. In terms of end users, the spinal cord stimulation devices for the chronic pain market are categorized into hospitals, ambulatory surgery centers, and others. The hospital segment held a larger share of the market in 2022 and is anticipated to register a higher CAGR during 2022-2030.

In September 2023, Resonant Link and Cirtec Medical Corp partnered to power the future of implantable medical devices. By combining Resonant Link's next-generation wireless power with Cirtec Medical's expert product design, development, and manufacturing services, this partnership will offer medical device makers the best technology, fully integrated components, and faster time to market.

Reasons to Buy:

Table Of Contents

1. Introduction

2. Europe and Middle East Spinal Cord Stimulation Device for Chronic Pain Market - Key Takeaways

3. Research Methodology

4. Europe and Middle East Spinal Cord Stimulation Device for Chronic Pain Market - Market Landscape

5. Europe and Middle East Spinal Cord Stimulation Device for Chronic Pain Market

6. Europe and Middle East Spinal Cord Stimulation Device for Chronic Pain Market - Regional Analysis

7. Europe and Middle East Spinal Cord Stimulation Device for Chronic Pain Market - Revenue and Forecast to 2030 - by Product Type

8. Europe and Middle East Spinal Cord Stimulation Device for Chronic Pain Market Revenue and Forecasts To 2030- by Application

9. Europe and Middle East Spinal Cord Stimulation Device for Chronic Pain Market Revenue and Forecasts To 2030- by End User

10. Europe and Middle East Spinal Cord Stimulation Device for Chronic Pain Market - Revenue and Forecast to 2030 - Regional Analysis

11. Europe and Middle East Spinal Cord Stimulation Device for Chronic Pain Market - Revenue and Forecast to 2030 - Regional Analysis

12. Industry Landscape

13. Company Profiles

14. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â